As Customs Requirements Change, SHARx Focuses on Rx Continuity for Employers and Patients

As changes under Executive Order 14411 and upcoming CBP mail entry rules threaten certain medication pathways, SHARx is proactively preparing alternative solutions to keep employee prescription access uninterrupted.

“The order is not a ban or a restriction on personally imported prescription drugs, but it could affect medication pathways, depending on how shipments are currently handled and how the government implements the requirements,” SHARx Co-Founder and Chief Growth Officer Paul Pruitt said. “It’s important for employers to understand that distinction while knowing we have built new pathways to prepare for potential changes.”